Acquisition History / PharmaEssentia Corporation / FORUS Therapeutics Inc.
PharmaEssentia Corporation Acquires FORUS Therapeutics Inc.
Announced June 11, 2026 — $36.5M
What happened
Taiwan-listed PharmaEssentia acquired its Canadian commercial partner FORUS Therapeutics, a Toronto-based haematology/oncology specialty pharma with established regulatory, medical and market-access infrastructure, to take direct control of its Canadian commercialisation.
- Acquirer
- PharmaEssentia Corporation
- Target
- FORUS Therapeutics Inc.
- Announced
- June 11, 2026
- Price
- $36.5M
- Industry
- Specialty pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did PharmaEssentia Corporation acquire FORUS Therapeutics Inc.?
PharmaEssentia Corporation acquired FORUS Therapeutics Inc. on June 11, 2026. This was PharmaEssentia Corporation's 1st publicly tracked acquisition out of 1 we have on record.
How much did PharmaEssentia Corporation pay for FORUS Therapeutics Inc.?
PharmaEssentia Corporation paid $36.5M for FORUS Therapeutics Inc..
What does FORUS Therapeutics Inc. do?
Taiwan-listed PharmaEssentia acquired its Canadian commercial partner FORUS Therapeutics, a Toronto-based haematology/oncology specialty pharma with established regulatory, medical and market-access infrastructure, to take direct control of its Canadian commercialisation.
What other Specialty pharmaceuticals companies has PharmaEssentia Corporation acquired?
FORUS Therapeutics Inc. is PharmaEssentia Corporation's only publicly tracked acquisition in Specialty pharmaceuticals so far.
More Specialty pharmaceuticals acquisitions
Zydus Lifesciences Ltd acquires Assertio Holdings Inc
$166.4M · 2026
Garda Therapeutics acquires Assertio Holdings, Inc.
$153.2M · 2026